Completed PHASE3 INTERVENTIONAL NCT00240695

A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment

An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions Brain Diseases Cognition Disorder Mental Disorders Nervous System Diseases

Interventions galantamine hydrobromide

Updated 5 times since 2017 Last updated: May 17, 2011 Started: May 31, 2003 Completion: May 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00240695, this PHASE3 trial focuses on Brain Diseases and Cognition Disorder and remains completed. Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., it has been updated 5 times since 2003, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.